The Advantages Of Providing Access To Unlicensed Medicines
Executive Summary
Providing access to novel medicines through early access programs or supplying markets where medicines remain unlicensed has key benefits for the innovative drug development industry; revealing market insights and strategic opportunities.
You may also be interested in...
UK: Commercial Framework Sheds Light On Working With NHS And NICE
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Time Is Ripe For Global Action On Orphan Biosimilars
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.
Time Is Ripe For Global Action On Orphan Biosimilars
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.
Need a specific report? 1000+ reports available
Buy Reports